ArticleCase reports in surgery2026
Case Report of Primary Splenic Angiosarcoma in a Young Patient: A Very Rare and Challenging Disease.
Article in Case reports in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Case Report of Primary Splenic Angiosarcoma in a Young Patient: A Very Rare and Challenging Disease.Case reports in surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Primary splenic angiosarcoma (PSA) is a rare type of angiosarcoma often associated with an unfavorable prognosis. The presenting symptoms are usually nonspecific, adding to the diagnostic difficulty of this disease. Limited cases have been described in younger adults, as most cases have been reported in individuals between 50 and 70 years old. Presentation of Case: We report the case of a 25-year-old patient with cerebral palsy who initially presented for high-grade fever and left upper quadrant (LUQ) pain. On computed tomography (CT) scan, a large heterogenous mass was discovered in the spleen, and the patient underwent total splenectomy with pathological analysis confirming the diagnosis of PSA. The patient had no further complications and is still clinically stable. Discussion: PSA's pathogenesis is not fully understood, though potential risk factors include exposure to chemicals or radiation, none of which were present in this case. Diagnosing PSA is challenging due to nonspecific symptoms and imaging findings that overlap with benign splenic lesions. Treatment primarily involves splenectomy, but prognosis remains poor due to the high likelihood of early metastasis. Adjuvant therapies, including chemotherapy and targeted agents, are under investigation. Conclusion: PSA is a rare and aggressive malignancy with significant diagnostic and therapeutic challenges. Early recognition and timely management may be important in selected cases, and outcomes remain poor, highlighting the need for further research to optimize treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.